Logo Blue Main.png
Neuronascent Announces the Expansion of its Board of Directors
April 12, 2023 06:00 ET | Neuronascent, Inc.
ROCKVILLE, Md., April 12, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., a clinical-stage, neuron generating, biopharmaceutical company, is pleased to announce the addition of industry leader Emer...
Oncotelic Announces Initiation of Clinical Study in Non-Small Lung Cell Cancer
February 06, 2023 08:00 ET | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications,...
Alterity’s ATH434 Prevents Loss of Brain Cells in Parkinson’s Disease Animal Model
MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation
January 10, 2023 10:15 ET | Silo Pharma, Inc.
Parkinson's disease, bipolar disorder, and chronic pain targeted in study Study aims to support psilocybin as a potential therapeutic for inflammatory disorders ENGLEWOOD CLIFFS,...
Zhittya Logo.jpg
Zhittya Genesis Medicine announces: Free Zoom Webinar: Zhittya Parkinson’s Disease Research Study: 6-Month Patient Follow-Up Report
December 19, 2022 12:00 ET | Zhittya Genesis Medicine Inc
LAS VEGAS, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya”), announced that they will be hosting a webinar on Tuesday, December 20, 2022, at 4:00 PM...
Clinical ink Selecte
Clinical ink Selected for Global Late Phase Parkinson’s Disease Programs
December 14, 2022 10:47 ET | Clinical Ink
Horsham, PA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Horsham, Pa.; December 14, 2022 — Clinical ink, a global life science technology company, has partnered with a leading biopharmaceutical organization...
Oncotelic Reports Q3 2022 Compared to Q3 2021 Financial Results
November 21, 2022 09:00 ET | Oncotelic Therapeutics, Inc.
R&D cost reduced in excess of 95% while continuing expansion of our OT-101 clinical programs through our joint ventureG&A cost reduced by approximately 50%Net loss reduced by approximately...
With 13% of CAGR, Neurological Biomarker Market to Gain $14+ Billion Revenue by 2027 | Exclusive Report by The Insight Partners
November 14, 2022 06:58 ET | The Insight Partners
New York, Nov. 14, 2022 (GLOBE NEWSWIRE) -- According to The Insight Partners latest study on "Neurological Biomarker Market Size, Share, Growth, Trends and Forecast to 2027 – COVID-19 Impact and...
youtube profile pic.png
Parkinson's Disease Drug Market is Pegged to Reach $12.3 Billion By 2028 | Levodopa is the Most Popular Drug
November 07, 2022 09:21 ET | SkyQuest Technology Consulting Pvt. Ltd.
Westford,USA, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Parkinson's disease is a debilitating neurological disorder that affects millions of people worldwide. As the population ages, the number of people...
Amydis Awarded Third Grant From The Michael J. Fox Foundation To Support First-In-Human Study of a Retinal Tracer for Parkinson’s Disease
October 27, 2022 07:00 ET | Amydis, Inc.
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Amydis Inc., a privately held clinical-stage company pioneering a platform of diagnostic drug candidates targeting molecular biomarkers in the eye, today...